HRSA Determines Six Manufacturers’ Contract Pharmacy Policies Violate 340B Statute
Yesterday, HRSA Acting Administrator Diana Espinosa sent letters to Eli Lilly, AstraZeneca, Novartis, Novo Nordisk, Sanofi, and United Therapeutics making clear to the manufacturers that their restrictions on access to 340B pricing at contract pharmacies “have resulted in overcharges and are in direct violation of the 340B statute.” As a result, HRSA is requiring the six manufacturers…